The fusion gun that isn't a power plant

Every weekday roughly 40,000 Americans get a cardiac, cancer or bone scan that depends on molybdenum-99, a radioactive tracer the United States does not make. It is flown in from aging research reactors in Europe, South Africa and Australia. The catch is physics: Mo-99 loses about 1% of its activity every hour, so by the time a shipment lands, roughly a third of what was loaded has already decayed to nothing.

The plant is named Chrysalis — the cocoon stage. SHINE's actual fusion-energy ambitions are the butterfly it hasn't built yet.

SHINE Technologies' Chrysalis plant in Janesville, Wisconsin is built to be the first domestic source. It works by a route that sounds like a fusion power plant and isn't: deuterium-tritium fusion generators fire a torrent of neutrons into tanks of liquid low-enriched uranium, and the neutrons split the uranium to yield Mo-99. The fusion is a neutron gun to spark fission. No electricity comes out.

The plant is already about 75-80% built; what was missing was the money to install the irradiation equipment. The Department of Energy's loan office has now agreed to provide up to $263 million over roughly fifteen years to finish it, with first commercial isotopes around 2027 and full output by the end of 2029. That makes a US-made medical-isotope supply, not fusion power, the thing a federal loan is backstopping.

One caveat sits at the center: this is a conditional commitment, not a signed and funded loan. DOE and SHINE still have to clear technical, legal, environmental and financial conditions before any money moves — a statement of intent to re-shore a supply chain the country has been trying to bring home since the global isotope shortages of 2009.